1415794-62-5Relevant articles and documents
HETEROCYCLIC COMPOUNDS
-
Paragraph 0262; 0263, (2017/03/21)
The present invention provides a heterocyclic compound a TLR7 and/or TLR9 and/or TLR-7/8/9 and/or TLR-7/8 and/or TLR-7/9 inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases and/or inflammatory diseases and the like, in particular, acute decompensated heart failure, non-alcoholic steatohepatitis (NASH), IgA nephropathy, Duchenne muscular dystrophy (DMD), systemic lupus erythematosus, Sjogren's syndrome, rheumatoid arthritis, psoriasis, inflammatory bowel disease, asthma, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, B-cell malignancies, transplant rejection and graft-versus-host disease, hepatocellular carcinoma (HCC) and the like. The present invention is a compound represented by the formula (1) : wherein each symbol is as described in the specification, or a salt thereof.
Palladium-mediated conversion of para-aminoarylboronic esters into para-aminoaryl-11C-methanes
Andersen, Valdemar L.,Herth, Matthias M.,Lehel, Szabolcs,Knudsen, Gitte M.,Kristensen, Jesper L.
supporting information, p. 213 - 216 (2013/02/22)
Cross-couplings are an alternative to conventional 11C- methylations which are generally employed in PET tracer synthesis. Therefore, we set out to develop a general procedure for the synthesis of para- 11CH3 labeled aromatic amines from the corresponding para-aminoarylboronic esters in the presence of free amines. Aryl boronic esters containing primary, secondary, and tertiary amines were successfully converted into corresponding labeled methyl derivatives in sufficient radiochemical yield to apply this method for tracer development. This procedure was applied to the labeling of CIMBI-712, a promising candidate for the in vivo imaging of the 5-HT7 receptor in the CNS.